Primmune Therapeutics, Inc. — Form D
Primmune Therapeutics, Inc. of San Diego, CA, a company, filed a Form D exempt-offering notice with the SEC on 2020-03-17. The offering totals $4.0M, of which $2.0M was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2020-03-17
- Form: D
- Accession: 0001721931-20-000003
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $4.0M
- Amount sold: $2.0M
- Remaining: $2.0M
- Investors: 17
- Date of first sale: 2019-02-04
- Revenue range: Decline to Disclose
- SEC file number: 021-362982
Issuer
- Name: Primmune Therapeutics, Inc.
- CIK: 0001721931
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2017
- Address: c/o JLABS San Diego, San Diego, CA, 92121
- Phone: 858-205-2281
Officers, directors & promoters (10)
| Name | Role | Location |
|---|
| Charles McDermott | Director | San Diego, CA |
| Charles McDermott | Executive Officer | San Diego, CA |
| Scott S Morenstein | Director | San Diego, CA |
| Andrew S Rubinstein | Director | San Diego, CA |
| Todd J Harris | Director | Carlsbad, CA |
| Paulo S Rangel | Director | Carlsbad, CA |
| Paulo S Rangel | Executive Officer | Carlsbad, CA |
| James R Appleman | Director | Carlsbad, CA |
| James R Appleman | Executive Officer | Carlsbad, CA |
| Amir S Nashat | Director | Cambridge, MA |
Other filings by this issuer (5)
More